Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Upgraded by Bank of America

Bank of America upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from an underperform rating to a neutral rating in a research report sent to investors on Friday morning, MarketBeat reports.

Separately, The Goldman Sachs Group initiated coverage on Bayer Aktiengesellschaft in a research note on Thursday, May 30th. They issued a neutral rating for the company. One research analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of Hold.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $8.01 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. The company has a market cap of $31.48 billion, a price-to-earnings ratio of -9.21 and a beta of 1.04. Bayer Aktiengesellschaft has a one year low of $6.82 and a one year high of $13.82. The firm has a 50 day simple moving average of $7.40 and a 200 day simple moving average of $7.43.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.25. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. The firm had revenue of $12 billion during the quarter. Research analysts predict that Bayer Aktiengesellschaft will post 1.37 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.